Cagent Vascular raises $41m for dual-modality IVL platform advancement

Cagent will use the funds to complete a pivotal trial of its Serranator SONIC IVL system and support commercial necessitates for the platform. Cagent will use the funds to complete a pivotal trial of its Serranator SONIC IVL system and support commercial necessitates for the platform. IVL has been gaining interest among medtech industry players since J&J’s $13.1bn acquisition of Shockwave Medical in June 2024. Credit: sciencepics / Shutterstock.com Cagent Vascular has raised $41m and completed the first-in-human use cases of its Serranator SONIC intravascular lithotripsy (IVL) platform. The Pennsylvania-based company’s Series D financing round was co-led by US Venture…

Source: Medical Device Network